Objective: To evaluate the efficacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in alleviating symptoms and improving the dysfunction of Kashin-Beck disease (KBD) patients. Methods: We undertook a cluster-randomized, placebo-controlled trial in 251 patients with KBD. Participants were randomly allocated to comparing (1) chondroitin sulfate, (2) glucosamine hydrochloride, (3) a combination of chondroitin sulfate and glucosamine hydrochloride, or (4) placebo, for 6 months duration. The primary outcome measures of interest were 20% and 50% reductions in pain from baseline, measured by pain subscale in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. Secondary outcome measures included parameters in the WOMAC Index such as pain, stiffness, and physical function, as well as patients' quality of life by the 12-item Short-Form General Health Survey. The trial registration number is ChiCTR-TRC-11001480 (http://www.chictr.org/). Results: A combination therapy of chondroitin sulfate and glucosamine hydrochloride was effective in reducing WOMAC pain by 20% (differences of 23.4%, P ¼ 0.006) and 50% (differences of 15.7%, P ¼ 0.016), WOMAC pain (P ¼ 0.032), WOMAC stiffness (P ¼ 0.043), and WOMAC total score (P ¼ 0.035). Chondroitin sulfate used alone was also found to be effective in reducing WOMAC total score and stiffness score (P ¼ 0.038 and P ¼ 0.023, respectively). No significant positive effects in improving WOMAC Index scores were observed with glucosamine hydrochloride alone. Conclusion: The findings of this study indicate that a combination of chondroitin sulfate and glucosamine hydrochloride was more effective than placebo in treating KBD.
Introduction
Kashin-Beck disease (KBD) is a degenerative osteoarticular disease affecting the bones and joints 1 . The core pathological feature of KBD is degradation of cartilages, which is similar to that in osteoarthritis (OA) 2 . Eventual joint destruction leads to recurrent and mostly bilateral joint pain, restriction of physical movement and joint enlargement 3 . The most frequently affected sites are the distal limb joints (e.g., ankles, knees, wrists and elbows) 4 . The worst forms of the disease tend to start in childhood and may result in dwarfism 5 . KBD is endemic to certain geographical areas, from South-Eastern Siberia to North Korea, North-East to South-West of China. About three million people are affected by KBD in China, Russia and North Korea 6 . There are various hypotheses regarding the etiology of KBD but the exact causes are unknown. It is likely that KBD has a multifactorial origin 7 .
Treatment of KBD is mainly for palliative care, and selenium supplementation has been given in some highly endemic areas for a long time. The efficacy of selenium supplementation for prevention and treatment of KBD, however, is uncertain 8e11 . There are other treatment options such as surgical corrections, physical treatment, and non-steroidal anti-inflammatory drugs. Regrettably most are not proven to be effective. Attention has thus been focused on applying treatment for OA in KBD as both conditions share a central pathological feature.
Chondroitin sulfate and glucosamine have been recognized as symptomatic, slow-acting remedies for OA for decades. Numerous studies have shown that glucosamine and chondroitin sulfate could relieve pain and delay long-term progression of knee OA in terms of joint structure changes and symptoms 12e15 . Furthermore, findings from a randomized controlled trial (RCT) showed that chondroitin sulfate and glucosamine were effective in slowing down knee joint space narrowing when compared to placebo in adult patients with KBD 16 . All the above suggest that chondroitin sulfate and glucosamine might play a protective role in preserving articular cartilage and thus could be potential therapeutic agents in patients with KBD. However, the aforementioned RCT did not measure pain relief, physical function, or quality of life improvement. Therefore, the complete benefits of chondroitin sulfate and/or glucosamine are yet to be established. With this aim in mind, we undertook a clusterrandomized, placebo-controlled trial to evaluate the efficacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in alleviating symptoms and improving the dysfunction of KBD patients during a 6-month treatment course.
Methods

Setting and participants
Our cluster-randomized, placebo-controlled trial was conducted in the Nanmuda village of Rangtang County, Sichuan, China, which is one of the endemic areas affected by KBD. Nanmuda village is a semi-farming and semi-husbandry tribe, in which all residents are Tibetan nationality. According to the epidemiological study, the detection rate of KBD is 39.1% in Rangtang County 17 . The recent 2008 survey by the Chinese Center for Disease Control and Prevention found that a total of 3641 residents lived in the Nanmuda village (1826 men and 1815 women), of whom 1079 were KBD patients. We recruited patients with KBD who were available to and capable of giving informed consent, and who planned to live in the trial areas for at least 6 months. There was no age limit. The clinical diagnosis and grading of KBD as well as differential diagnosis with other bone disease (e.g., OA, osteofluorosis and rheumatoid arthritis) were made by orthopedic surgeons and physicians of the Rheumatology Department of West China Hospital, Sichuan University on the basis of clinical and radiological criteria (GB 16003-1995) 18 . Patients were excluded on the following criteria: (1) they had taken any medications for KBD during 3 months before enrollment; (2) they had a history of, or evidence of, specified confounding disorders (e.g., septic arthritis, neoplasias, bone metabolic diseases, or OA); (3) history of clinically significant trauma or surgery to the index joint; (4) co-existing diseases that could preclude successful completion of the trial; (5) and pregnancy. The trial protocol was approved by the Institutional Review Boards at West China Hospital and was conducted according to Good Clinical Practice guidelines and the Helsinki Declaration II. Full informed consent (by signature or thumbprint) was obtained from all trial participants. The trial registration number is ChiCTR-TRC-11001480 (http://www.chictr.org/).
Procedures
For the baseline observational period, the results of routine laboratory tests were collected, and clinical symptoms and physical examination assessments were conducted. Eligible patients, in clusters, were randomly assigned to one of four orally administered treatments: (1) 600 mg of chondroitin sulfate twice daily, (2) 480 mg glucosamine hydrochloride three times daily, (3) a combination of glucosamine plus chondroitin sulfate as above, or (4) placebo (consisted of starch only), for a period of 6 months. Chondroitin sulfate was manufactured by Green Pharmaceutical Factory, Chongqing, China. It contained 100 mg of sodium chondroitin sulfate A (chondroitin-4-sulfate) per tablet, which was from extracts of cartilaginous pig tissues (trachea, ear and nose). This product has been approved as a supplement for OA at a dosage regime of 1200 mg per day in China. Glucosamine used in this study was manufactured by Xin Si Dun Pharmaceutical Factory (Sichuan Province, China). It contained 240 mg of D-glucosamine hydrochloride per tablet. It is approved as a supplement for OA at a dosage of 1480 mg per day in China.
Chondroitin sulfate and glucosamine are both slow-acting remedies and thus are unable to relieve pain during the first 2 weeks of administration. In order to improve compliance, participants in each group were allowed to take an additional 200 mg of celecoxib (Celebrex, Pfizer) daily during the first 2 weeks after randomization for pain relief. Participants in four groups must have equal access to celecoxib to avoid interference to outcomes. Other analgesics, including narcotics and paracetamol, were prohibited. Home visits were carried out every 2 weeks. Village doctors gathered data on dosage that patients had missed, number of unused sachets and any occurrence of adverse events from the time of randomization to the end of the 6-month treatment course. Participants were evaluated 6 months after randomization.
Randomization and allocation concealment
The patients were divided into clusters of family. The randomization list was generated by a computer in blocks of four, and every family received their randomization number in chronological order. The principal investigator was provided with single-sealed, opaque envelopes, which contained the randomization codes for every family cluster. Trial personnel had no access to the randomization list or any information that would allow them to deduce or manipulate the allocation sequence. Chondroitin sulfate, glucosamine, and placebo were different in numbers of tablets and appearance and we did not use dummy intervention. However, their identities were masked by naming them as "A", "B", "C" and "D". Therefore, although the participants and trial personnel (including those distributing medicine and collecting, processing, and analyzing data) were aware that the medications were different they were unable to identify the exact type of medications.
Outcome measures
The primary outcome measure was a response to treatment, defined as a 20% and 50% decrease in the summed score for the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscale from baseline to sixth month. The secondary outcome measures included the mean change in WOMAC total scores and subscale scores (including pain, stiffness, and physical function) after 6 months of treatment. The mean change in quality of life as measured by the 12-item Short-Form General Health Survey (SF-12) was also evaluated.
The WOMAC Index is a validated, disease-specific questionnaire addressing severity of joint pain (five questions), stiffness (two questions), and limitation of physical function (seventeen questions). The worst possible total score is 96 19 . SF-12, reflecting the health-related quality of life, evaluates physical function (six questions) and mental function (six questions), with a score range from 6 to 56 20 . To prevent methodological errors and assure methodological reliability, the administrator was trained by the investigator by: (1) reviewing the WOMAC and SF-12 procedures and grading system outlined in a short booklet and video;
(2) observing an experienced rheumatologists in the conduct of WOMAC and SF-12 procedures.
Adverse events
Safety variables included adverse events, serious adverse events and laboratory evaluations. Adverse events were graded according to qualitative assessment of the extent or intensity of the adverse events by the investigator, or reported by the patients. Serious adverse events were defined as any fatal or immediate lifethreatening clinical experience or disabling event. Laboratory evaluations included complete blood counts, measurement of serum alanine transaminase (ALT), glutamic-oxalacetic transaminase (AST), alkaline phosphatase (ALP), urea nitrogen (BUN), creatinine (CREA), uric acid (UA), and glucose (GLU).
Statistical analysis
We calculated sample size on the basis of outcomes of Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) 21 . Incidences of reducing pain by 20% were 64.1%, 65.4% and 66.6% in the glucosamine group, the chondroitin sulfate group, and the combined-treatment group, respectively. Assuming a rate of response of 35% in the placebo group, a Type I error of 5%, and a Type II error of 20%, a sample size of 196 patients (49 participants per group) was calculated, and this was increased to at least 248 patients (62 participants per group) to take into account an expected dropout rate of 20%. The sample size was calculated using the following formula which is suitable for multiple comparisons:
The chi-square test was used to compare categorical data (e.g., primary outcomes). Comparisons of each of the three treatment groups with the placebo group were made with a Type 1 error at 0.017 for each comparison (adjusted for three primary comparisons against placebo). One-way Analysis of Variance (ANOVA) followed by post-hoc test (Dunnett's test) was used to evaluate quantitative data (e.g., secondary outcomes). Multiple comparisons of each of the three treatment groups with the placebo group were made with a Type 1 error at 0.05. Analyses of the categorical data (e.g., primary outcomes) were conducted according to the intention-to-treat principle. A per-protocol analysis was performed in quantitative data (e.g., secondary outcomes). All statistical tests were two sided. We used Statistical Product and Service Solutions (SPSS) 13.0 software for all statistical analyses.
Results
Baseline characteristics
Recruitment began on nineteenth June, 2009 in Nanmuda villages of Rangtang county, Sichuan, China, and was completed on eighth July, 2010. A total of 764 participants were screened, of which 251 (from 38 families) were randomized. Participants were divided into four groups by the cluster randomization method to receive either chondroitin sulfate (n ¼ 64), glucosamine hydrochloride (n ¼ 62), a combination of chondroitin sulfate and glucosamine (n ¼ 63), or placebo (n ¼ 62) (Fig. 1 ). The most common reasons for exclusion were not meeting full inclusion criteria (n ¼ 312) and not agreeing to blood samples being taken (n ¼ 186). Majority of participants were female (54.6%). The age of participants ranged from 13 to 86 years with a mean age of 51.73 years. The mean body mass index (BMI) was 23.82 and the mean course of KBD was 25 years. The four groups had no significant differences at baseline (Table I) , and the withdrawal rate of 43/251 (17.1%) did not differ significantly amongst groups (Fig. 1 ). Fig. 1 . Trial profile.
Clinical outcomes
Results of primary outcome measures are given in Table II . The rate of response (20% decrease in WOMAC pain) in the combination group was significantly higher than that in the placebo control (differences of 23.4%, P ¼ 0.006). Although the rates of response in the chondroitin sulfate group and glucosamine group were higher than placebo (differences of 18%, and 8.1%, respectively), there was no statistical significance. The response rates of 50% decrease in WOMAC pain showed a similar pattern, with insignificant differences between placebo group and chondroitin sulfate group (differences of 12.2%, P ¼ 0.049) as well as glucosamine group (differences of 11.3%, P ¼ 0.068). The combination groups (differences of 15.7%, P ¼ 0.016) being statistically superior to the placebo group.
For secondary outcome measures (Table III) , the combined therapy was significantly better than placebo in reducing WOMAC total score (P ¼ 0.035), WOMAC pain (P ¼ 0.032) and WOMAC stiffness score (P ¼ 0.043). WOMAC total score and stiffness score were also significantly improved with chondroitin sulfate than with placebo (P ¼ 0.038 and P ¼ 0.023, respectively). Effects by glucosamine as compared to placebo were insignificant. For WOMAC function score and the SF-12, there were no significant differences between the placebo group and the chondroitin sulfate, glucosamine, or combination groups.
Adverse events
Adverse events reported were generally mild and evenly distributed amongst groups. A total of 23 adverse events were reported in 18 patients. No serious adverse events were reported. The number of patients who withdrew because of adverse events was similar among the groups (Fig. 1) . The incidence of adverse events was similar across the four groups (Table IV) . In general, notable abnormal laboratory test results did not follow any clinically relevant pattern in any treatment group.
Discussion
Due to an increased prevalence of KBD and a lack of effective therapies, many studies on treatment of KBD were carried out in recent years. One meta-analysis demonstrated the benefits of selenium supplementation for the primary prevention of KBD in children 22 . Chinese and Russian orthopedists have also reported successful treatment of joint defects by surgical means 23, 24 . Some authors have employed physical therapy in the treatment of KBD since it can relieve pain, improve mobility and thus improve the socio-economic status of patients 25, 26 . A 6-week RCT found that celecoxib and meloxicam provided effective relief from the symptoms of KBD (WOMAC pain and stiffness) 27 . Another study found that intra-articular injections of sodium hyaluronate can improve the function in knee of patients and relieve their symptoms of KBD 28 . Up to now, main issues in caring for patients with KBD are effective pain relief as well as improving their functional disability.
Our study demonstrated that combinatory chondroitin sulfate and glucosamine hydrochloride therapy was more effective in terms of treatment response (20% and 50% decrease in WOMAC pain, respectively). Both the combination or chondroitin sulfate alone were effective in relieving the joint stiffness, but they failed to improve overall physical function and quality of life measured by SF-12. No significant benefits were identified with the use of glucosamine hydrochloride. Adverse events reported were similar amongst treatment and placebo groups. Contrary to available research findings, we did not identify an increase in blood GLU with the administration of glucosamine. We noted a low success rate in improving WOMAC scores as well as worsening of symptoms with the use of placebo. This may be explained by the fact that our included participants were forbidden to take any additional analgesics besides 2 weeks of celecoxib. Since most of our participants had taken corticosteroids or paracetamol for management of their symptoms many years before taking part in our study, conditions could have been aggravated with the lack of co-interventions in the placebo group.
Chondroitin sulfate and glucosamine are used widely in OA and their efficacy and safety profiles in the treatment of OA are well established. Due to the similar pathological features of KBD and OA, we thereby investigated the applicability of chondroitin sulfate and glucosamine in KBD. Our study showed that combinatory chondroitin sulfate and glucosamine therapy were effective in relieving joint pain and improving joint stiffness. Our results are in agreement with some previous studies 12e15, 29, 30 . Particularly, the famous GAIT study showed that a combination of chondroitin sulfate and glucosamine may be effective in patients with moderate to severe symptoms of OA 21 . In addition, one study used chondroitin sulfate and glucosamine to treat adult patients with KBD for 8 months. It found that treatment with chondroitin sulfate and glucosamine in KBD was associated with an absence of change in femorotibial joint space width 16 . Chondroitin sulfate is a glycosaminoglycan with a polymerized disaccharide base linked to a sulfate group and is found in the proteoglycans of articular cartilage 31 . Glucosamine is an aminosaccharide which acts as a preferred substrate for the biosynthesis of glycosaminoglycan chains and, subsequently, for the production of aggrecan and other proteoglycans in cartilage 32 . In addition, sulfate salts have been suggested to be an important component in glucosamine's mechanism of action by elevating levels of glucosamine metabolites 33, 34 . This may explain the significant results in our study when glucosamine hydrochloride was coadministered with chondroitin sulfate. Chondroitin sulfate and glucosamine might play a protective role in preserving articular cartilage and provide evidence for therapeutic drugs in adult patients with KBD.
Interestingly, our study found that glucosamine hydrochloride was ineffective in the treatment of KBD. This result was inconsistent with other published data which confirmed the positive effects of glucosamine for OA 12e15,35e37 . However, there is already some conflicting evidence on the effectiveness of glucosamine in OA 38e43 . Using an anterior cruciate ligament deficient model of acute OA in the rabbit and daily glucosamine hydrochloride dosing for 8 weeks, starting 3 weeks after surgery, effects on most outcomes were insignificant 44 . One meta-analysis evaluated the effects of chondroitin sulfate and/or glucosamine on joint pain and radiological progression of OA of the hip or knee. On a 10-cm visual analog scale, the overall difference in pain intensity, glucosamine hydrochloride did not show any significant effect when compared to placebo. For glucosamine sulfate, there is a marginally significant difference compared with placebo. However, after excluded low quality studies (e.g., non-blinded, not taken intention-to-treat analysis, no concealment of allocations), glucosamine sulfate was also had no significant difference 42 . Another Cochrane review of glucosamine for OA found that glucosamine was ineffective for alleviating pain 45 . How do we explain the difference between the positive in vitro effects against the negative effects of glucosamine shown in some published clinical trials? A possible explanation could be the pharmacodynamics profile of glucosamine. In vitro studies demonstrated that plasma concentrations of 50e5000 mmol/L are required for glucosamine to exert therapeutic effect in OA 46 . However, as reported by Biggee et al. in a study of 18 participants with OA who were given 1500 mg of glucosamine sulfate after an overnight fast. Their peak serum glucosamine concentrations were detected at 90e180 min, with a range of 1.9e11.5 mmol/L 47 .
This phenomenon raises questions about the current biological rationale of glucosamine usage that are based on in vitro effects only observed at high concentrations.
Our study has a number of limitations. Firstly, the duration of follow-up was relatively short. Some outcomes such as WOMAC physical function and quality of life measured by SF-12 could not be effectively assessed in such a short duration. Secondly, the evaluation was only performed at 6-month with no assessment between baseline to 6 months. This was due to tough circumstances in Tibetan Plateau with restricted access, high altitude of >4000 m and limited local medical equipment. Furthermore, participants lived in scattered, remote areas and were difficult to re-group them for assessment. Thirdly, blinding was not performed in our study. However, scattered living conditions limited communication and contamination. The patients would hardly know what they were being allocated and how it could be different from another family member. Finally, the outcome measures included were WOMAC scores and SF-12, instead of the impersonal outcomes such as reduction of joint space width. This was due to practical problems. The outcome measure of joint space width is based on the effectiveness of X-ray treatment. Rangtang Country is a remote mountainous area and only one X-ray machine is available in the main country hospital. Participants must therefore walk 10e30 km in treacherous conditions to reach the country hospital. Therefore it was difficult to provide X-ray follow-up examination for every participant.
In conclusion, the findings of our study indicate that a combination of chondroitin sulfate and glucosamine hydrochloride is more effective than placebo in treating KBD (for joint pain and stiffness). Chondroitin sulfate alone was also effective in relieving joint stiffness. Chondroitin sulfate and glucosamine hydrochloride were found to be relatively safe in our 6-month treatment period. Continuing research is needed to establish the long-term effects and safety of chondroitin sulfate and glucosamine hydrochloride, and the efficacy of X-ray examination for KBD patients. In fact, we have planned to undertake a following study to observe the effect of chondroitin sulfate and glucosamine on KBD for 3 years with a follow-up visit every 3 months.
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